SCOTTSDALE, Ariz. Nov. 18, 2009 TGen Drug Development (TD2) and the Institut Paoli-Calmettes (IPC) have forged a strategic alliance that will enable both to maximize their worldwide contributions in the treatment of cancer patients.
The partnership between TD2, a Scottsdale subsidiary of the Phoenix-based Translational Genomics Research Institute (TGen), and Marseille, France-based IPC's comprehensive cancer center will enable both non-profit institutes to speed research discoveries to patients with cancer.
Both organizations will expand their clinical research network to evaluate new therapies in the U.S. and Europe in an effort to more quickly introduce new drugs into clinical trials.
Teams from both TD2 and IPC will focus their efforts on discovering molecular alterations within cancers and finding biomarkers that will help identify new therapeutic targets that can be used to tailor treatments for individual patients.
IPC and TD2 will collaborate on a number of primary tumor and metastasis in selected cancers, as well as initiate an exchange program for medical oncologists between the two institutions.
"Aligning with IPC represents a significant opportunity for TD2 and TGen to further expand our research affiliations into Europe," said Dr. Daniel Von Hoff, TGen's Physician-In-Chief. "In addition to our ongoing collaborations with Luxembourg, this new alliance with IPC will further our goals across both Europe and the United States of providing better treatments in a more timely fashion to our many patients who suffer from a variety of cancer types."
Professor Patrice Viens, a medical oncologist and General Director of IPC, said the alliance with TD2 will enable IPC to bridge new international relationships: "This alliance with TD2 translates to our continuing efforts to expand our collaborations in basic research and medical activities beyond Europe.''
IPC is one of the largest university-af
|Contact: Steve Yozwiak|
The Translational Genomics Research Institute